ArticleNature communications2026
Bridging hydrogen-bond-stabilized polymeric coacervate core micelles for high-efficiency drug encapsulation and delivery.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Functionalized Coacervates for Cancer Therapy: Advances and Prospects in Phase-Separation-Based Intelligent Drug Delivery.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Polymeric nanoparticles represent one of the most promising classes of non-lipid-based drug delivery vehicles. However, their clinical translation remains limited by poor drug loading capacity and suboptimal delivery efficiency. We here develop one type of polymeric nanoparticles, referred to as PCCMs (Polymeric Coacervate Core Micelles), which are assembled from a sulfoxide-containing block polymer. Hydrophobic drugs can be efficiently encapsulated into PCCMs via a fast, low-energy "Mix-and-Go" approach, reducing reliance on organic solvents and simplifying the drug-loading process. Moreover, PCCMs show high drug loading capacities and improved stability towards versatile hydrophobic drugs. Upon evaluating 40 different drugs, 45% of the tested compounds achieve drug loading contents exceeding 40%, 80% exceed 30%, and 100% surpass 20%. Both quantitative structure-property relationship (QSPR) calculations and experimental methods identify that hydration water within PCCMs' self-coacervated cores acts as the molecular barrier, substantially inhibiting long-range-ordered drug molecule packing and stabilizing drug aggregates at the nanoscale via bridging hydrogen bonds among the polymer-water-drug. Finally, we demonstrate that PCCMs exhibit significantly higher systemic delivery efficacy compared to commercial polymeric micelle formulations in female BALB/c mice. The high loading capacity, versatility, and efficacy of PCCMs pave the way for the clinical translation of polymeric nanoparticles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.